References
- RedekopWKMladsiDThe faces of personalized medicine: a framework for understanding its meaning and scopeValue Health2013166S4S924034312
- CooperNJSuttonAJAdesAEPaisleySJonesDRUse of evidence in economic decision models: practical issues and methodological challengesHealth Econ200716121277128618034447
- ClaxtonKExploring uncertainty in cost-effectiveness analysisPharmacoeconomics200826978179818767898
- ContiRVeenstraDLArmstrongKLeskoLJGrosseSDPersonalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research prioritiesMed Decis Making201030332834020086232
- PhillipsKAVan BebberSLMeasuring the value of pharmacogenomicsNat Rev Drug Discov20054650050915915153
- PhillipsKASakowskiJATrosmanJDouglasMPLiangSYNeumannPThe economic value of personalized medicine tests: what we know and what we need to knowGenet Med201416325125724232413
- HatzMHSchremserKRogowskiWHIs individualized medicine more cost-effective? A systematic reviewPharmacoeconomics201432544345524574059
- International Society for Pharmacoeconomics and Outcomes ResearchPharmacoeconomic Guidelines Around the World2015 Available from: http://www.ispor.org/peguidelines/index.aspAccessed February 26, 2015
- National Institute for Health and Care Excellence (NICE)Guide to the Methods of Technology Appraisal2013 Available from: http://www.nice.org.uk/media/D45/1E/GuideToMethodsTechnologyAppraisal2013.pdfAccessed May 1, 2014
- PhillipsKAVan BebberSLA systematic review of cost-effectiveness analyses of pharmacogenomic interventionsPharmacogenomics2004581139114915584880
- VegterSJansenEPostmaMJBoersmaCEconomic evaluations of pharmacogenetic and genomic screening programs: update of the literatureDrug Dev Res2010718492501
- VegterSBoersmaCRozenbaumMWilffertBNavisGPostmaMJPharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelinesPharmacoeconomics200826756958718563949
- WongWBCarlsonJJTharianiRVeenstraDLCost effectiveness of pharmacogenomics: a critical and systematic reviewPharmacoeconomics201028111001101320936884
- PhillipsKASakowskiJALiangSYPonceNAEconomic perspectives on personalized health care and preventionForum Health Econ Policy201316230
- GodmanBFinlaysonAECheemaPKPersonalizing health care: feasibility and future implicationsBMC Med20131117923941275
- AnnemansLRedekopKPayneKCurrent methodological issues in the economic assessment of personalized medicineValue Health2013166S20S2624034308
- BuchananJWordsworthSSchuhAIssues surrounding the health economic evaluation of genomic technologiesPharmacogenomics201314151833184724236483
- CraigDMcDaidCFonsecaTStockCDuffySWoolacottNAre adverse effects incorporated in economic models? A survey of current practiceInt J Technol Assess Health Care201026332332920584362
- US Food and Drug AdministrationPharmacogenomic Biomarkers in Drug Labeling2014 Available from: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htmAccessed May 1, 2014
- WilliamsIMMcIverSMooreDBryanSThe use of economic evaluations in NHS decision-making: a review and empirical investigationHealth Technol Assess20081271175
- Centre for Reviews and DisseminationNHS Economic Evaluation Database Handbook2007 Available from: http://www.york.ac.uk/inst/crd/pdf/nhseed-handbook2007.pdfAccessed May 1, 2014
- HusereauDDrummondMPetrouSCHEERS Task ForceConsolidated health economic evaluation reporting standards (CHEERS) statementBMJ2013346f104923529982
- IslerJAVesterqvistOEBurczynskiMEAnalytical validation of genotyping assays in the biomarker laboratoryPharmacogenomics20078435336817391073
- WeissSTMcLeodHLFlockhartDACreating and evaluating genetic tests predictive of drug responseNat Rev Drug Discov20087756857418587383
- FleemanNMartin SaboridoCPayneKThe clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic reviewHealth Technol Assess201115331102
- FerrusiILMarshallDAKulinNALeighlNBPhillipsKALooking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analysesPer Med20096219321520668661
- ElkinEBWeinsteinMCWinerEPKuntzKMSchnittSJWeeksJCHER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysisJ Clin Oncol200422585486314990641
- BlankPRSchwenkglenksMMochHSzucsTDHuman epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategiesBreast Cancer Res Treat2010124249750720364309
- ParkinsonBPearsonSAVineyREconomic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critiqueEur J Health Econ20141519311223436142
- HicksJKSwenJJThornCFClinical Pharmacogenetics Implementation ConsortiumClinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressantsClin Pharmacol Ther201393540240823486447
- CrewsKRGaedigkADunnenbergerHMClinical Pharmacogenetics Implementation ConsortiumClinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotypeClin Pharmacol Ther201291232132622205192
- CraigDMcDaidCFonsecaTStockCDuffySWoolacottNAre adverse effects incorporated in economic models? An initial review of current practiceHealth Technol Assess2009136217197181
- ShabaruddinFHChenLCElliottRAPayneKA systematic review of utility values for chemotherapy-related adverse eventsPharmacoeconomics201331427728823529208
- NoordzijMTripepiGDekkerFWZoccaliCTanckMWJagerKJSample size calculations: basic principles and common pitfallsNephrol Dial Transplant20102551388139320067907
- PirmohamedMBurnsideGErikssonNEU-PACT GroupA randomized trial of genotype-guided dosing of warfarinN Engl J Med2013369242294230324251363
- KimmelSEFrenchBKasnerSEA pharmacogenetic versus a clinical algorithm for warfarin dosingN Engl J Med2013369242283229324251361
- NewmanWGPayneKTrickerKTARGET Study Recruitment TeamA pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET studyPharmacogenomics201112681582621692613
- SvenssonSMenkesDBLexchinJSurrogate outcomes in clinical trials: a cautionary taleJAMA Intern Med2013173861161223529157
- SorichMJRowlandAWieseMDPharmacogenomic substudies of randomized controlled trials: consideration of safety outcomesTher Adv Drug Saf201452626625083262
- US National Institutes of HealthNational Cancer InstituteCommon Terminology Criteria for Adverse Events (CTCAE)2013 Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htmAccessed February 25, 2015
- FlemingTRPowersJHBiomarkers and surrogate endpoints in clinical trialsStat Med201231252973298422711298
- FlemingTRDeMetsDLSurrogate end points in clinical trials: are we being misled?Ann Intern Med199612576056138815760
- ShabaruddinFHEconomic Evaluation of the UGT1A1 Pharmacogenetic Test[dissertation]Manchester, UKThe University of Manchester2011
- SorichMJCooryMInterpreting the clinical utility of a pharmacogenomic marker based on observational association studiesPharmacogenomics J20141411524018622
- CaudleKEKleinTEHoffmanJMIncorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development processCurr Drug Metab201415220921724479687
- EpsteinRSMoyerTPAubertREWarfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study)J Am Coll Cardiol201055252804281220381283
- JohnsonJAGongLWhirl-CarrilloMClinical Pharmacogenetics Implementation ConsortiumClinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosingClin Pharmacol Ther201190462562921900891
- AndersonJLHorneBDStevensSMA randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II)Circulation2012125161997200522431865
- BurmesterJKBergRLYaleSHA randomized controlled trial of genotype-based Coumadin initiationGenet Med201113650951821423021
- MayersCPanzarellaTTannockIFAnalysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinomaCancer200191122246225711413512
- CameronDAMassieCKerrGLeonardRCModerate neutropenia with adjuvant CMF confers improved survival in early breast cancerBr J Cancer200389101837184214612889
- TinkerAVSpeersCBarnettJOlivottoIAChiaSImpact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I-II breast cancersEcancermedicalscience200826322275960
- DrummondMFSculpherMTorranceGO’BrienBJStoddartGMethods for the Economic Evaluation of Health Care ProgrammesOxford, UKOxford University Press2005
- PayneKFish and chips all round? Regulation of DNA-based genetic diagnosticsHealth Econ200918111233123619821463
- ThompsonAJNewmanWGElliottRARobertsSATrickerKPayneKThe cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprineValue Health2014171223324438714
- GarberAMTunisSRDoes comparative-effectiveness research threaten personalized medicine?N Engl J Med2009360191925192719420360
- SculpherMDrummondMBuxtonMThe iterative use of economic evaluation as part of the process of health technology assessmentJ Health Serv Res Policy199721263010180650
- DoumaKFKarsenbergKHummelMJBueno-de-MesquitaJMvan HartenWHMethodology of constructive technology assessment in health careInt J Technol Assess Health Care200723216216817493301
- PhilipsZBojkeLSculpherMClaxtonKGolderSGood practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessmentPharmacoeconomics200624435537116605282
- ShabaruddinFHElliottRAValleJWNewmanWGPayneKUnderstanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United KingdomBr J Cancer2010103331532320661248
- SullivanWPayneKThe appropriate elicitation of expert opinion in economic models: making expert data fit for purposePharmacoeconomics201129645545921568356
- LealJWordsworthSLegoodRBlairEEliciting expert opinion for economic models: an applied exampleValue Health200710319520317532812
- O’HaganABuckCEDaneshkhahAUncertain Judgements: Eliciting Experts’ Probabilities (Statistics in Practice)ChichesterWiley2006
- SculpherMClaxtonKEstablishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty – when is there sufficient evidence?Value Health20058443344616091019
- BeaulieuMde DenusSLachaineJSystematic review of pharmacoeconomic studies of pharmacogenomic testsPharmacogenomics201011111573159021121811
- TowseAGarrisonLPJrEconomic incentives for evidence generation: promoting an efficient path to personalized medicineValue Health2013166 SupplS39S4324034311
- European Medicines AgencyReflection Paper on Methodological Issues Associated with Pharmacogenomic Biomarkers in Relation to Clinical Development and Patient Selection2011 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/07/WC500108672.pdfAccessed February 23, 2015 EMA/446337/2011
- CoffeyCSLevinBClarkCOverview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshopClin Trials20129667168023250942
- KairallaJACoffeyCSThomannMAMullerKEAdaptive trial designs: a review of barriers and opportunitiesTrials20121314522917111
- NewmanWPayneKRemoving barriers to a clinical pharmacogenetics servicePer Med200855471480
- McKinnonRAWardMBSorichMJA critical analysis of barriers to the clinical implementation of pharmacogenomicsTher Clin Risk Manag20073575175918473000
- US Food and Drug AdministrationDraft Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics2011 Available from: http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdfAccessed February 23, 2015
- PharmGKBDosing Guidelines – CPIC2015 Available from: http://www.pharmgkb.org/view/dosing-guidelines.do?source=CPIC#Accessed February 25, 2015
- ByronSKCrabbNGeorgeEMarlowMNewlandAThe Health Technology Assessment of companion diagnostics: experience of NICEClin Cancer Res20142061469147624634470
- ClaxtonKPSculpherMJUsing value of information analysis to prioritise health research: some lessons from recent UK experiencePharmacoeconomics200624111055106817067191
- US Food and Drug AdministrationFDA Basics. What is the Approval Process for a New Prescription Drug?2014 Available from: http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194949.htmAccessed February 25, 2015
- Medicines and Healthcare Products Regulatory AgencyApply for a Licence to Market a Medicine in the UK Detailed Guidance2014 Available from: https://www.gov.uk/apply-for-a-licence-to-market-a-medicine-in-the-ukAccessed February 25, 2015
- European Medicines AgencyHuman Medicines: Regulatory Information2015 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/landing/human_medicines_regulatory.jsp&mid=Accessed February 25, 2015
- National Institute for Health and Care Excellence (NICE)Specification for Manufacturer/Sponsor Submission of Evidence2014 Available from: https://www.nice.org.uk/proxy/?sourceurl=http://www.nice.org.uk/aboutnice/howwework/devnicetech/specificationformanufacturersponsorsubmissionofevidence.jspAccessed February 25, 2015
- PayneKAnnemansLReflections on market access for personalized medicine: recommendations for EuropeValue Health2013166S32S3824034310
- DavisJCFurstenthalLDesaiAAThe microeconomics of personalized medicine: today’s challenge and tomorrow’s promiseNat Rev Drug Discov20098427928619300459
- FugelHJNuijtenMPostmaMStratified medicine and reimbursement issuesFront Pharmacol2012318123087645
- DeverkaPAVernonJMcLeodHLEconomic opportunities and challenges for pharmacogenomicsAnnu Rev Pharmacol Toxicol20105042343720055709
- FleemanNMcLeodCBagustAThe clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluationHealth Technol Assess2010143115720031087
- WillkeRJCrownWDel AguilaMCzirakyMJKhanZMMiglioriRMelding regulatory, pharmaceutical industry, and US payer perspectives on improving approaches to heterogeneity of treatment effect in research and practiceValue Health2013166 SupplS10S1524034306
- FruehFWRegulation, reimbursement, and the long road of implementation of personalized medicine – a perspective from the United StatesValue Health2013166S27S3124034309
- Medical Research CouncilStratified Medicine2015 Available from: http://www.mrc.ac.uk/research/initiatives/stratified-medicine/Accessed February 26, 2015